Download Files:
Products Details
Product Description
– EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2)[1].
Web ID
– HY-144056
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C24H25ClN6O3
References
– [1]Yihan Wang, et al. Substituted acrylamide derivatives and compositions thereof and their uses. Patent WO2021185348A1.
CAS Number
– 2711105-48-3
Molecular Weight
– 480.95
SMILES
– O=C(C1=C(C(C2CN(CCC2)C(C=C)=O)=NN1C3=CC=C(C(Cl)=C3)OCC4=NC=CC=C4)N)N
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– EGFR
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
